Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

1 Top Penny Stock to Watch Now

Penny stocks, especially in the early-stage biotech sector, often tend to be volatile and highly risky, but they also offer the potential for massive rewards. One such company is BioXcel Therapeutics (BTAI), which stands out right now for its late-stage pipeline progress, rising market potential, and approaching FDA milestone, making it a top penny stock to keep an eye on for 2026.

BioXcel Therapeutics is a biopharmaceutical company that employs artificial intelligence (AI) and machine learning to discover and develop breakthrough treatments, with a focus on neuroscience. By using AI, the company aims to lower the cost and time needed for...

Fundamentals

See More
  • Market Capitalization, $K 40,239
  • Shares Outstanding, K 21,869
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -59,600 K
  • EBIT $ -51 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.21
  • Price/Sales 18.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 78.13%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 675.37% on 01/24/25
  • IV Low 0.00% on 01/13/26
  • Expected Move (DTE 0) 0.0425 (2.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 200
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 8,803
  • Open Int (30-Day) 8,763
  • Expected Range 1.7975 to 1.8825

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.58
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.82
  • Prior Year -3.57
  • Growth Rate Est. (year over year) +83.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +22.67%
on 12/30/25
2.1200 -13.21%
on 01/07/26
-0.0400 (-2.13%)
since 12/16/25
3-Month
1.5000 +22.67%
on 12/30/25
2.4799 -25.80%
on 10/17/25
-0.6200 (-25.20%)
since 10/16/25
52-Week
1.1700 +57.26%
on 05/30/25
8.0800 -77.23%
on 08/12/25
-3.6928 (-66.74%)
since 01/16/25

Most Recent Stories

More News
1 Top Penny Stock to Watch Now

This small-cap biotech is chasing a big breakthrough in 2026.

BTAI : 1.8400 (-3.66%)
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BTAI : 1.8400 (-3.66%)
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home...

BTAI : 1.8400 (-3.66%)
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines...

BTAI : 1.8400 (-3.66%)
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered...

BTAI : 1.8400 (-3.66%)
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience,...

BTAI : 1.8400 (-3.66%)
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BTAI : 1.8400 (-3.66%)
H.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $10.00. The company’s shares closed yesterday at $2.68.Elevate Your...

BTAI : 1.8400 (-3.66%)
BioXcel Announces Positive SERENITY At Home Study Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

BTAI : 1.8400 (-3.66%)
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience,...

BTAI : 1.8400 (-3.66%)

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 2.0483
2nd Resistance Point 2.0067
1st Resistance Point 1.9233
Last Price 1.8400
1st Support Level 1.7983
2nd Support Level 1.7567
3rd Support Level 1.6733

See More

52-Week High 8.0800
Fibonacci 61.8% 5.4404
Fibonacci 50% 4.6250
Fibonacci 38.2% 3.8096
Last Price 1.8400
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar